FDA Regulatory Filing

The FDA has listed ANDA 208458 in the Drugs@FDA database as an approval record for the generic version of levetiracetam. This is a product in the marketed stage, based on bioequivalence, and not in the clinical development stage. The reference drug is Keppra (UCB.BR) from UCB. The ANDA listing indicates that the generic drug has demonstrated equivalent efficacy, quality, and therapeutic performance to the reference drug, rather than presenting new efficacy data. This highlights the importance of increased patient access and price competition.

Drug and Regulatory History

Levetiracetam, the active ingredient in Keppra, is an antiepileptic drug that binds to synaptic vesicle glycoprotein 2A (SV2A) and regulates neurotransmitter release and excessive neuronal excitation. It is used alone or in combination to treat partial seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures. The FDA approved Keppra tablets on November 30, 1999, and the intravenous formulation on July 31, 2006. ANDAs primarily focus on quality, manufacturing, and bioequivalence assessments, rather than requiring an advisory committee review. On November 28, 2023, the FDA added a warning about rare but serious DRESS drug reactions to levetiracetam.

Market and Competitive Landscape

The global levetiracetam market was estimated at approximately USD 1.62 billion in 2025 and is projected to reach USD 2.95 billion in 2031. With over 50 million people worldwide suffering from epilepsy, and ongoing demand for both oral and intravenous formulations in emergency rooms and intensive care units, the market supports significant volume. However, the entry of multiple generic versions necessitates a separate analysis of revenue growth and manufacturer margins. Key competitors in the standard treatment market include lamotrigine (Lamictal), valproate (Depakote), and lacosamide (Vimpat). Briviact (brivaracetam), which belongs to the same SV2A family, is a direct competitor based on its mechanism of action.

Investment and Business Implications

This filing demonstrates the competitive intensity within the mature generic supply chain, rather than highlighting clinical success or the acquisition of exclusivity. Levetiracetam benefits from a broad prescription base and long-term use. However, the increasing number of ANDAs accelerates price reductions and bidding competition, limiting excess profits for individual products. For UCB, defending the Keppra brand is less critical than transitioning to subsequent neurological products such as Briviact. For generic manufacturers, profitability depends on manufacturing costs, supply chain stability, and securing access to hospital channels.